• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

来那度胺诱导的自身免疫性肠病并发多发性骨髓瘤合并系统性肥大细胞增多症的治疗

Lenalidomide-induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis.

作者信息

Lakritz Stephanie, Forsberg Peter A, Sherbenou Daniel W, Mark Tomer M

机构信息

Department of Medicine, Division of Hematology University of Colorado School of Medicine Aurora Colorado USA.

出版信息

Clin Case Rep. 2022 Sep 19;10(9):e6199. doi: 10.1002/ccr3.6199. eCollection 2022 Sep.

DOI:10.1002/ccr3.6199
PMID:36188028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9483819/
Abstract

Lenalidomide is an IMiD drug which has been associated with a variety of potential immune related complications. We describe the case of a patient with newly diagnosed multiple myeloma along with a history of systemic mastocytosis who developed evidence of an autoimmune enteropathy shortly after initiating lenalidomide based therapy.

摘要

来那度胺是一种免疫调节药物，与多种潜在的免疫相关并发症有关。我们描述了一例新诊断的多发性骨髓瘤患者，该患者有系统性肥大细胞增多症病史，在开始基于来那度胺的治疗后不久出现了自身免疫性肠病的证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cc2/9483819/3174852e02cc/CCR3-10-e6199-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cc2/9483819/1f14486a0500/CCR3-10-e6199-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cc2/9483819/3174852e02cc/CCR3-10-e6199-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cc2/9483819/1f14486a0500/CCR3-10-e6199-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cc2/9483819/3174852e02cc/CCR3-10-e6199-g001.jpg

相似文献

1
Lenalidomide-induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis.来那度胺诱导的自身免疫性肠病并发多发性骨髓瘤合并系统性肥大细胞增多症的治疗
Clin Case Rep. 2022 Sep 19;10(9):e6199. doi: 10.1002/ccr3.6199. eCollection 2022 Sep.
2
Evidence-based mechanisms of synergy with IMiD agent-based combinations in multiple myeloma.在多发性骨髓瘤中，与 IMiD 药物联合应用的协同作用的循证机制。
Crit Rev Oncol Hematol. 2023 Aug;188:104041. doi: 10.1016/j.critrevonc.2023.104041. Epub 2023 Jun 1.
3
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.卡非佐米或硼替佐米联合来那度胺和地塞米松治疗无即刻自体干细胞移植意向的新诊断多发性骨髓瘤患者（ENDURANCE）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.
4
B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.老年男性患浆细胞骨髓瘤伴长期沙利度胺和来那度胺暴露后的 B 细胞急性淋巴细胞白血病：病例报告及文献复习。
BMC Cancer. 2019 Nov 27;19(1):1147. doi: 10.1186/s12885-019-6286-9.
5
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.来那度胺、硼替佐米和地塞米松联合伊沙妥昔单抗用于新诊断、适合移植的多发性骨髓瘤患者的诱导治疗（GMMG-HD7）：一项开放标签、多中心、随机、主动对照、3 期临床试验的第 1 部分。
Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0.
6
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.加拿大来那度胺治疗多发性骨髓瘤后的治疗模式和结局的回顾性研究。
Eur J Haematol. 2021 Oct;107(4):416-427. doi: 10.1111/ejh.13678. Epub 2021 Jun 27.
7
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.每周卡非佐米、来那度胺、地塞米松和达雷妥尤单抗联合治疗新诊断多发性骨髓瘤患者的安全性和有效性：MANHATTAN 非随机临床试验。
JAMA Oncol. 2021 Jun 1;7(6):862-868. doi: 10.1001/jamaoncol.2021.0611.
8
IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?无免疫调节药物（IMiD）间期与IMiD用药顺序：哪种策略更适合来那度胺难治性骨髓瘤？
Life (Basel). 2023 Nov 20;13(11):2229. doi: 10.3390/life13112229.
9
Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.探索预测多发性骨髓瘤患者对免疫调节衍生物反应的基因特征：一项使用前瞻性临床试验微阵列数据集的探索性回顾性研究。
Lancet Haematol. 2017 Sep;4(9):e443-e451. doi: 10.1016/S2352-3026(17)30143-6.
10
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.硼替佐米联合来那度胺和地塞米松与单纯来那度胺和地塞米松治疗新诊断的无立即自体干细胞移植意向的骨髓瘤患者（SWOG S0777）：一项随机、开放标签的3期试验
Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23.

引用本文的文献

1
Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors.影响多发性骨髓瘤 T 细胞功能：塞利尼索和 XPO1 抑制剂的潜在作用。
Front Immunol. 2023 Oct 26;14:1275329. doi: 10.3389/fimmu.2023.1275329. eCollection 2023.

本文引用的文献

1
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs.了解 T 细胞在免疫调节药物抗骨髓瘤效应中的作用。
Front Immunol. 2021 Mar 5;12:632399. doi: 10.3389/fimmu.2021.632399. eCollection 2021.
2
A Rare Case of Systemic Mastocytosis with Associated Hematologic Neoplasm (SM-AHN) Involving Chronic Myeloid Leukemia: A Case Report and Literature Review.全身性肥大细胞增多症伴相关血液肿瘤（SM-AHN）累及慢性髓性白血病：病例报告及文献复习。
Am J Case Rep. 2020 May 13;21:e923354. doi: 10.12659/AJCR.923354.
3
Relevant updates in systemic mastocytosis.
系统性肥大细胞增多症的相关更新。
Leuk Res. 2019 Jun;81:10-18. doi: 10.1016/j.leukres.2019.04.001. Epub 2019 Apr 4.
4
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.成人系统性肥大细胞增生症：诊断、危险分层和治疗的 2019 年更新。
Am J Hematol. 2019 Mar;94(3):363-377. doi: 10.1002/ajh.25371. Epub 2019 Jan 2.
5
Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.来那度胺-地塞米松方案治疗复发/难治性多发性骨髓瘤患者期间的继发性原发性恶性肿瘤
Cancer Med. 2017 Jan;6(1):3-11. doi: 10.1002/cam4.799. Epub 2016 Nov 18.
6
History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.自身免疫性疾病史与多发性骨髓瘤及意义未明的单克隆丙种球蛋白病患者生存率降低相关：一项基于人群的研究。
Ann Hematol. 2017 Feb;96(2):261-269. doi: 10.1007/s00277-016-2859-8. Epub 2016 Nov 2.
7
Mastocytosis.肥大细胞增多症
Prim Care. 2016 Sep;43(3):505-18. doi: 10.1016/j.pop.2016.04.007.
8
Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro.来那度胺在体内和体外均可增强骨髓瘤特异性T细胞反应。
Oncoimmunology. 2016 Feb 18;5(5):e1139662. doi: 10.1080/2162402X.2016.1139662. eCollection 2016 May.
9
Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.多发性骨髓瘤和意义未明的单克隆丙种球蛋白病患者的自身免疫表现。
BBA Clin. 2016 May 25;6:12-8. doi: 10.1016/j.bbacli.2016.05.004. eCollection 2016 Dec.
10
Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case.伴有冒烟型多发性骨髓瘤的系统性肥大细胞增多症：一例报告
Case Rep Oncol Med. 2016;2016:3161768. doi: 10.1155/2016/3161768. Epub 2016 May 16.